The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer
Abstract Objective Immunotherapy has led to changes in cervical cancer guidelines. Therefore, additional biomarkers to identify the ideal patient who would experience the most benefit may be important. Methods We retrospectively collected 208 patients with R/M CC and recorded clinicopathologic infor...
Saved in:
| Main Authors: | Mingxiu Ju, Baoyue Pan, Yongwen Huang, Yun Zhou, Jieping Chen, Huiling Xiang, Shije Xu, Siyu Chen, Chunyan Lan, Jundong Li, Min Zheng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-10-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70204 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunotherapy for Recurrent and Metastatic Cervical Cancer: A Review
by: Yuke Wu, et al.
Published: (2024-07-01) -
Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study
by: Jian Chen, et al.
Published: (2025-07-01) -
A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancerResearch in context
by: Qiang Wen, et al.
Published: (2025-07-01) -
Immunotherapy in cervical cancer: an innovative approach for better treatment outcomes
by: Treshita Dey, et al.
Published: (2025-03-01) -
The safety of combining Endostar with concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer and the evaluation of its anti-angiogenic effects via transrectal contrast-enhanced ultrasound
by: Fang Wu, et al.
Published: (2025-05-01)